leisure time -WSS

leisure time

author：leisure time 2025-09-27 09:58:56 - browse：41

An light blue number 3 with an eye is surrounded by smaller, black number 3s on an orange background — 3 to watch coverage from STAT — Christine Kao/STAT

It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was hard to come by, and valuations were down. On the policy side, the industry grappled with changing AI regulations, reimbursement woes, and device sterilization rules.

Here are three political and market forces that shaped the medtech industry last year, and are worth paying attention to in 2024:

Lobbying power of AI, software-enabled devices

Medtech lobby AdvaMed announced earlier this month that the major medical imaging companies, previously housed within the National Electrical Manufacturers Association, were shifting to their shop. The device group also created a separate niche for digital health companies in October.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： UnitedHealth quietly bought dozens of outpatient centers

focus

WSS

Why the drug industry's warnings on the IRA's impact fall short

Patients, doctors press FTC to beef up hospital merger scrutiny

IVF, abortion rights issues kick off Biden’s State of the Union

Free Covid tests will again be offered to all U.S. households

Change Healthcare payments predicted restored March 15

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

focus

leisure time

Lobbying power of AI, software-enabled devices

focus

ChatGPT in medicine: STAT answers readers' burning questions

Transgender sports debate: Physicians say bans are health issue

Apple is now the first public company to be valued at $3 trillion

IVF, abortion rights issues kick off Biden’s State of the Union

In age of alternative facts, a scholarly course on calling out crap

IVF, abortion rights issues kick off Biden’s State of the Union

Hollywood unions extend contract negotiations for actors

What it’s like to watch children die of measles

Hepatitis C has a cure — but many Americans still lack access to it

Fed up with FDA, ALS advocates consider a take

leisure time

Akili changes sales model for its ADHD video game treatment

Amylyx ALS drug failure raises questions and concerns

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Senate bill would ban some hospital facility fees

David Liu startup to focus on CRISPR delivery

Amylyx ALS drug failure raises questions and concerns

leisure time

focus

explore

focus